References
- Bhargava A, Jackson WB, El-Defrawy SR. Ocular allergic disease. Drugs Today 1998;34(10;957–971.
- Cipriandi GC, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clin Immunother 1996; 5;374–391.
- Ciprandi G, Buscaglia S, Cerqueti PM,Canonica GW. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 1992;43:154–176.
- Joss J, Craig T. Seasonal allergic conjunctivitis. Drugs Today 1998; 34(3):259–265.
- Brodkin RN, Sorkin EM. Nedocromil sodium: an updated review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1993;45;693–715.
- Blumenthal M, Casale T, Dockhorn R, Jarmoszuk I, Kaiser H, Smith R, Zeit HJ. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1992;113:56–63.
- Koch GG, Can GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical data analysis. In: Berry DA, editor. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker, 1989.
- Leino M, Carlson C, Jaanio E, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Ann Allergy 1990;64; 398–402.
- Stockwell A, Easty DL. Group comparative trial of 2% nedocromil sodium with placebo in the treatment of seasonal allergic conjunctivitis. Eur J Ophthalmol 1994;4:19–23.
- Moller C, Berg I-M, Berg T, Kjellman M, Stromberg L. Nedocromil sodium 2% eye drops for twice-daily treatment of seasonal allergic conjunctivitis: a Swedish multicentre placebo-controlled study in children allergic to birch pollen. Clin Exp Allergy 1994;24(9):884–887.
- Van Bijsterveld OP, Moons L, Verdonck M, Kempeneers HP. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate. Ocul Immunol Inflamm 1994;2:177–186.
- Benbow AG, Eady R, Jackson D. The immunopharmacological actions of nedocromil sodium relative to the use of its 2% ophthalmic solution. Eye 1993;7\(Pt 3 Suppl):26–28.
- Bissonnette EY, Enciso JA, Befus AD. Inhibition of tumour necrosis factor-alpha (TNF-a) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium. Clin Exp Immunol 1995;102: 78–84.
- Gonzalez JP, Brogden RN. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and the therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987;34:560–577.
- Corin RE. Nedocromil sodium: a review of the evidence for a dual mechanism of action. Clin Exp Allergy 2000;30(4):461–468.